2014
DOI: 10.4161/cbt.29523
|View full text |Cite
|
Sign up to set email alerts
|

A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(8 citation statements)
references
References 44 publications
0
8
0
Order By: Relevance
“…Hence, if the majority of highly active KIT oncoproteins are located intracellularly, the effect of the antibody on plasma membrane–associated KIT could be masked by a dominant intracellular KIT activation. This could explain why we see a lack of effect under CK6 treatment in the GIST xenografts tested, while CK6 showed KIT antagonist effects in melanoma, small cell lung carcinoma, and leukemia research models [14] . Therefore, we would suggest further studies characterizing the binding properties of anti-KIT monoclonal antibodies to the GIST mutant KIT receptor along with thorough analysis of KIT receptor localization in GIST models.…”
Section: Discussionmentioning
confidence: 90%
See 1 more Smart Citation
“…Hence, if the majority of highly active KIT oncoproteins are located intracellularly, the effect of the antibody on plasma membrane–associated KIT could be masked by a dominant intracellular KIT activation. This could explain why we see a lack of effect under CK6 treatment in the GIST xenografts tested, while CK6 showed KIT antagonist effects in melanoma, small cell lung carcinoma, and leukemia research models [14] . Therefore, we would suggest further studies characterizing the binding properties of anti-KIT monoclonal antibodies to the GIST mutant KIT receptor along with thorough analysis of KIT receptor localization in GIST models.…”
Section: Discussionmentioning
confidence: 90%
“…Furthermore, SR1 inhibited tumor growth also in vivo in GIST882 and GIST430 xenograft models. Another KIT antibody, CK6, has recently demonstrated KIT antagonist activity and tumor growth neutralizing properties in melanoma and small cell lung carcinoma [14] . In the present study, we tested the efficacy of CK6 in six GIST human xenograft models characterized by different sensitivity to standard TKI treatment.…”
Section: Introductionmentioning
confidence: 99%
“…For example, activating mutations in the c-KIT receptor are present in a small percent of human SCLC tumors 15, 32 (Figure 2), and activation of this receptor by its ligand SCF can promote ERK1/2 activity in SCLC cells 33–36 , though in certain contexts SCLC cells respond to SCF binding independently of ERK1/2 37 .…”
Section: Main Textmentioning
confidence: 99%
“…C-kit is a receptor of the stem cell factor, the activation of which is considered crucial for cell proliferation and migration (38). Of note, the activation of c-kit has been reported to attribute to the cell proliferation and cirrhosis of HCC (39).…”
Section: Discussionmentioning
confidence: 99%